Literature DB >> 22169201

Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy.

Shunmei Chiba1, Erika Takada, Mamoru Tadokoro, Taizo Taniguchi, Keiichi Kadoyama, Mariko Takenokuchi, Seiya Kato, Noboru Suzuki.   

Abstract

Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) is a family of inherited dementias caused by tauopathy. A mutation in exon 10 of the tau gene, N279K, causes a particular kindred of FTDP-17, which is predominant for parkinsonism. The disease initially presents as L-dopa resistant parkinsonism which then rapidly progresses. The final pathological features reveal disappearing dopamine (DA) neurons, but the causes remain poorly understood. We previously established a transgenic mouse with human N279K mutant tau as a model for FTDP-17, which showed cognitive dysfunctions caused by the mutant. Here we analyze L-dopa resistant parkinsonism by several behavioral tests, and focus on the distributions and accumulations of the mutant tau in the DA system by immunohistochemistry and Western blot. Interestingly, dopaminoreceptive (DAr) neurons in the striatum showed neurofibrils degeneration and apoptosis through caspase-3 activation by mutant tau accumulation. The DAr neuron loss in the caudoputamen, the target of the nigrostriatal system occurred before DA neuron loss in young symptomatic mice. Residual DA neurons in the mouse functioned in DA transportation, whereas dysregulation of intracellular DA compartmentalization implied an excess level of DA caused by DAr neuron loss. In the final stages, both DAr and DA neurons decreased equally, unlike Parkinson's disease. Therefore, DAr neurons were fundamentally vulnerable to the mutation indicating a critical role for the L-dopa resistant parkinsonism in tauopathy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169201     DOI: 10.1016/j.neurobiolaging.2011.11.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  5 in total

1.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

2.  Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

Authors:  Allyson V McCormick; Jeanna M Wheeler; Chris R Guthrie; Nicole F Liachko; Brian C Kraemer
Journal:  Biol Psychiatry       Date:  2012-11-07       Impact factor: 13.382

3.  DOPA Decarboxylase Modulates Tau Toxicity.

Authors:  Rebecca L Kow; Carl Sikkema; Jeanna M Wheeler; Charles W Wilkinson; Brian C Kraemer
Journal:  Biol Psychiatry       Date:  2017-06-15       Impact factor: 13.382

4.  Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging.

Authors:  Jin Yong Hong; Mun Kyung Sunwoo; Jungsu S Oh; Jae Seung Kim; Young H Sohn; Phil Hyu Lee
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

5.  miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.

Authors:  Yong-Bo Hu; Yong-Fang Zhang; Hao Wang; Ru-Jing Ren; Hai-Lun Cui; Wan-Ying Huang; Qi Cheng; Hong-Zhuan Chen; Gang Wang
Journal:  Cell Death Dis       Date:  2019-08-05       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.